Position in RCUS
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$554
New position
Shares Held
18
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#216
of 228 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Evolution Advisers, Inc. holds $8,255 across 22 Biotechnology names. RCUS ranks #6 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TGTX |
Tg Therapeutics, Inc.
|
15 | $824 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
9 | $782 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
2 | $743 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
2 | $632 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
5 | $612 | |
| 6 | RCUS |
Arcus Biosciences, Inc.
This page
|
18 | $554 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1 | $496 | |
| 8 | FTRE |
Fortrea Holdings Inc.
|
26 | $452 |
All Filings in RCUS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $554 | 18 | Shares | Sole | 2026-07-31 | |
| No filing history on record for this holder in this stock. | ||||||